News

Flixabi is now approved to treat rheumatoid arthritis, Crohn’s disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and psoriasis. Flixabi demonstrated comparable safety and equivalent efficacy to Remicade in

Checkpoint will develop and commercialize these small molecule inhibitors in solid tumors. The BET inhibitor program is the subject of an exclusive, worldwide license agreement pursuant to which

On average 50 percent of Hodgkin lymphoma patients relapse after ASCT and those patients with additional risk factors can be at even higher risk of relapse. ADCETRIS after

This follows Kitov’s announcement in December 2015, that KIT-302’s pivotal Phase III trial successfully met its primary efficacy endpoint. Kitov CEO Isaac Israel said: "We are fortunate to

Teduglutide is an analogue of human glucagon like peptide 2 (GLP-2) that enhances key structural and functional adaptations in the intestinal mucosa. The European Commission (EC) will now

Children born with ADA-SCID do not have a fully functioning immune system and are unable to fight off common infections. The disease affects nearly 15 children a year

The study compared Faslodex 500mg (fulvestrant) to Arimidex 1mg (anastrozole) to treat locally-advanced or metastatic breast cancer, in post-menopausal women who have not had prior hormonal treatment for

Zinbryta is a humanized IgG1 monoclonal antibody that selectively binds to the high-affinity interleukin-2 (IL-2) receptor subunit (CD25), a protein that is over-expressed on T cells that become

The Probuphine subdermal implant, which utilizes Titan’s proprietary ProNeura technology, delivers buprenorphine continuously for up to six months. The product is expected to be commercially available this summer